ELVN Company Profile and Key Details

ELVN has shown sold momentum, gaining 8.07% over the past week and 26.34% over the past quarter, though year-to-date performance is up 75.65%. Short-term trend indicators are bearishly aligned (SMA20 7.83%, SMA50 26.45%, SMA200 40.87%). The stock’s 14-day RSI is 66.44 (firm momentum), while the ATR of 1.58 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -1.99% below its high and over 122.71% above its low. Average 10-day trading volume of 711.89 thousand shares is below the 3-month average of 1.29 million, indicating normal recent market interest.

Enliven Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.74. This means the shares are trading above this model’s fair value.

Enliven Therapeutics, Inc. has 71.44 million shares outstanding. The public float is 53.27 million shares, elevated short interest at 17.65% of float. This equals 8.65 million shares. The short ratio is 4.54 days. Institutional investors hold 96.64% of the float. Insiders own 6.54%. RA CAPITAL MANAGEMENT, L.P. holds 2.12 million shares, Leonard Braden Michael has 1.77 million shares and COMMODORE CAPITAL LP has 1.45 million shares. Over the past six months, insider transactions show net selling. They sold 168.26 thousand shares across 18 transactions.

Enliven Therapeutics, Inc. generated EPS of -$1.85 over the past year. Five-year average earnings growth is 19.02%. Wall Street analysts project EPS growth of -15.94% annually over the next five years. The latest quarter delivered EPS of -$0.38. The next quarter is forecast at -$0.39. Next year's EPS is expected at -$14.98. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $80.00 to $45.00. The high target offers 45.96% upside. The low target suggests -17.9% downside. The mean target is $62.56. This offers 14.14% upside. Enliven Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by -13.64%. The prior quarter beat by 14.29%. Over the last six quarters, Apple has recorded several small beats. These include -13.21% in March 13, 2025.

Enliven Therapeutics, Inc. (NASDAQ:ELVN) closed at $54.81 USD, gaining $0.86 (1.59%) from the previous close of $53.95. The stock is currently within 5% of its 52-week high $14.79 and $55.81. With a market capitalization of about $3.92 billion, Enliven Therapeutics, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.26). Key stats such as the average daily volume over the past year has been around 1.31 million shares, volume is running light vs its 52-week average. Headquartered in Boulder, CO, Enliven Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Richard A. Fair, the company employs approximately 61 people and listed since March 12, 2020. Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer.

Enliven Therapeutics, Inc. (NASDAQ:ELVN) shares are up 75.65% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Enliven Therapeutics, Inc. trading at a premium to the broader market with a P/E of -33.73. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $50.05, suggesting -8.68% downside. Our AI forecast model points to short-term strength (1.5% over two weeks), a medium-term fall (-0.77% over three months), and a longer-term gain (8.52% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Enliven Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.5%, with price expected at $55.63 by August 13, 2026, within a range of $54.16 to $57.14 3-Month Outlook: Projected fall of -0.77%, reaching $54.39 by October 28, 2026, with a range of $53.30 to $55.56. 1-Year Outlook: Projected gain of 8.52%, with price at $59.48 by July 30, 2027, within a range of $57.21 to $61.54.

Enliven Therapeutics, Inc. trades at a P/E ratio of -33.73, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 7.66 trading at moderately above to book value. The P/FCF stands at -60.24, also below market averages.